| scholarly article | Q13442814 |
| P50 | author | George Sledge | Q92594250 |
| Edith A. Perez | Q18389345 | ||
| P2093 | author name string | Robert Gray | |
| Roberto Bugarini | |||
| Nancy E Davidson | |||
| Sunil Badve | |||
| Joseph A Sparano | |||
| Lawrence N Shulman | |||
| Silvana Martino | |||
| Diana Brassard | |||
| Steven Shak | |||
| Barrett H Childs | |||
| Frederick L Baehner | |||
| Lori J Goldstein | |||
| Steve Rowley | |||
| P2860 | cites work | Gene expression of topoisomerase II alpha (TOP2A) by microarray analysis is highly prognostic in estrogen receptor (ER) positive breast cancer | Q45215625 |
| Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory | Q46589624 | ||
| American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. | Q51925963 | ||
| Exposure stratified case-cohort designs. | Q52079932 | ||
| Benefit of taxanes as adjuvant chemotherapy for early breast cancer | Q61899631 | ||
| TAILORx: trial assigning individualized options for treatment (Rx) | Q79339663 | ||
| An investigation of two multivariate permutation methods for controlling the false discovery proportion | Q79938773 | ||
| Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system | Q80358653 | ||
| HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials | Q80408348 | ||
| Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401 | Q83305244 | ||
| Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients | Q24561669 | ||
| A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer | Q28297827 | ||
| Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials | Q29547513 | ||
| Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer | Q29616112 | ||
| Measurement of gene expression in archival paraffin-embedded tissues: development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay | Q31034429 | ||
| Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer | Q33845160 | ||
| Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer | Q33996115 | ||
| Side effects of adjuvant treatment of breast cancer | Q34295656 | ||
| HER-2 and topoisomerase II as predictors of response to chemotherapy | Q34747499 | ||
| American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. | Q35951294 | ||
| Development of the 21-gene assay and its application in clinical practice and clinical trials | Q37079600 | ||
| Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197 | Q37125089 | ||
| Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features | Q37125093 | ||
| DNA topoisomerase II as the primary target of anti-tumor anthracyclines | Q37562611 | ||
| Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels: predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil | Q38450735 | ||
| Thymidylate synthase expression predicts the response to 5-fluorouracil-based adjuvant therapy in pancreatic cancer | Q44602894 | ||
| Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer | Q44902909 | ||
| Weighted analyses for cohort sampling designs | Q45158000 | ||
| P433 | issue | 24 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | chemotherapy | Q974135 |
| P304 | page(s) | 7693-7700 | |
| P577 | publication date | 2009-12-01 | |
| P1433 | published in | Clinical Cancer Research | Q332253 |
| P1476 | title | Relationship between Topoisomerase 2A RNA Expression and Recurrence after Adjuvant Chemotherapy for Breast Cancer | |
| P478 | volume | 15 |
| Q43787894 | A metastasis biomarker (MetaSite Breast™ Score) is associated with distant recurrence in hormone receptor-positive, HER2-negative early-stage breast cancer |
| Q41498719 | Ancestry as a potential modifier of gene expression in breast tumors from Colombian women. |
| Q34805496 | Assessment of Topoisomerase II α status in breast cancer by quantitative PCR, gene expression microarrays, immunohistochemistry, and fluorescence in situ hybridization |
| Q37822734 | Do anthracyclines still have a role in adjuvant chemotherapy of breast cancer? |
| Q55066764 | Predictive role of HER2/neu, topoisomerase-II-alpha, and tissue inhibitor of metalloproteinases (TIMP-1) for response to adjuvant taxane-based chemotherapy in patients with intermediate-risk breast cancer: results from the WSG-AGO EC-Doc trial. |
| Q55346547 | Prognostic gene expression assays in breast cancer: are two better than one? |
| Q36349584 | Prognostic significance of TOP2A gene dosage in HER-2-negative breast cancer |
| Q36554725 | Prognostic value of biologic subtype and the 21-gene recurrence score relative to local recurrence after breast conservation treatment with radiation for early stage breast carcinoma: results from the Eastern Cooperative Oncology Group E2197 study |
| Q37376754 | Quantum dot-based immunofluorescent imaging and quantitative detection of TOP2A and prognostic value in triple-negative breast cancer |
| Q36603829 | Relationship between quantitative GRB7 RNA expression and recurrence after adjuvant anthracycline chemotherapy in triple-negative breast cancer |
| Q36598709 | Sample parameters affecting the clinical relevance of RNA biomarkers in translational breast cancer research |
| Q37136305 | TOP2A RNA expression and recurrence in estrogen receptor-positive breast cancer |
| Q37989074 | Topoisomerase 2 alpha: a real predictor of anthracycline efficacy? |
| Q37862646 | Use of standard markers and incorporation of molecular markers into breast cancer therapy: Consensus recommendations from an International Expert Panel |
| Q31103913 | Validation of the Cancer BioChip System as a 3D siRNA screening tool for breast cancer targets |
Search more.